ERBB2 and breast carcinoma: Recently, however, the antibody–drug conjugate, trastuzumab deruxtecan, has proven highly efficacious in patients with relapsed refractory breast cancer in which HER2 expression is present, but at levels below those required to define the tumour as HER2+ [33].